Delving into the Latest Updates on CGT-6321 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target

Mechanism

FGFRs antagonists(Fibroblast growth factor receptors antagonists), VEGFR antagonists(Vascular endothelial growth factor receptor antagonists)

Therapeutic Areas

Neoplasms

Active Indication

Advanced Malignant Solid Neoplasm

Inactive Indication

Liver CancerStomach Cancer

Originator Organization

CGeneTech (Suzhou, China) Co. Ltd.

Active Organization

CGeneTech (Suzhou, China) Co. Ltd.

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

主要目的：评价CGT-6321片在晚期实体瘤患者中的安全性和耐受性。次要目的：评价CGT-6321片在晚期实体瘤患者体内的药代动力学(PK)特征；初步评价CGT-6321片的抗肿瘤疗效。探索性目的：探索CGT-6321片的药效动力(PD)学特征，初步摸索具有疗效响应的实体瘤瘤种。

[Translation]

Primary objective: To evaluate the safety and tolerability of CGT-6321 tablets in patients with advanced solid tumors. Secondary objective: To evaluate the pharmacokinetic (PK) characteristics of CGT-6321 tablets in patients with advanced solid tumors; To preliminarily evaluate the anti-tumor efficacy of CGT-6321 tablets. Exploratory objective: To explore the pharmacodynamic (PD) characteristics of CGT-6321 tablets and preliminarily explore solid tumor types with therapeutic response.

Start Date27 Jun 2022

Sponsor / Collaborator

CGeneTech (Suzhou, China) Co. Ltd.

100 Clinical Results associated with CGT-6321

Login to view more data

100 Translational Medicine associated with CGT-6321

Login to view more data

100 Patents (Medical) associated with CGT-6321

Login to view more data

100 Deals associated with CGT-6321

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Liver Cancer	Phase 2	CN	CGeneTech (Suzhou, China) Co. Ltd.	19 Oct 2021
Stomach Cancer	Phase 2	CN	CGeneTech (Suzhou, China) Co. Ltd.	19 Oct 2021
Advanced Malignant Solid Neoplasm	Phase 1	CN	CGeneTech (Suzhou, China) Co. Ltd.	27 Jun 2022